Pancreatic Adenosquamous Carcinoma clinical trials at UCSF
2 research studies open to eligible people
Pancreatic adenosquamous carcinoma is a rare cancer in the pancreas. UCSF is studying if giving chemotherapy before and after surgery is better than just after surgery. Another trial is testing the best drug combination for patients with certain genetic mutations.
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
open to eligible people ages 18 years and up
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
San Francisco, California and other locations
PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
open to eligible people ages 18 years and up
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
San Francisco, California and other locations
Last updated: